Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-OCV in Healthy Adults and Children
NCT02823899Phase 2Completed
- Sponsor
- icddr,b
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Hillchol in cholera, sponsored by icddr,b. Primary endpoints: Vaccine related reactogenicity at 30 months and Solicited adverse events at 7 days. Started Jul 2016; status: completed.
02
Drugs
Hillchol
03
Conditions
cholera
Beyond the preview
Go deeper on NCT02823899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823899.